On July 12, 2022, Beilu participated in the seventh batch of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use Joint Procurement Off...
Beijing Beilu Pharmaceutical Co., Ltd. (300016) announced today that Gadobutrol injection has obtained the "Drug Registration Certificate" issued by the NMPA(National Medial Production Administr...
The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...
Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...
Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...
To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Haichang Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...
Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...